Results 191 to 200 of about 24,744 (229)

Thiazolidinediones and cardiovascular disease

Current Atherosclerosis Reports, 2005
Thiazolidinediones hold promise for reducing cardiovascular events and human atherosclerosis. Similar to statins and angiotensin-converting enzyme inhibitors, peroxisome proliferator activated receptor gamma (PPARgamma) exerts anti-inflammatory and antiatherosclerotic actions in the vessel wall.
Robert, Chilton, Elaine, Chiquette
openaire   +2 more sources

Vascular reactivity and thiazolidinediones

The American Journal of Medicine, 2003
Endothelial dysfunction is a critical factor in the development of vascular disease in patients with diabetes mellitus. Maintenance of the vascular tone and luminal diameter of a blood vessel is dependent on the net balance of vasoconstrictor and vasodilator forces. In both diabetes and obesity, vascular reactivity is abnormal.
Paresh, Dandona, Ahmad, Aljada, Ajay, Chaudhuri   +2 more
openaire   +2 more sources

Thiazolidinediones

Highlights: Introduction Pharmacology Treatment Advantages/Disadvantages Therapeutic Considerations Monographs ...
Kam L. Capoccia, Peggy Soule Odegard
openaire   +1 more source

Where thiazolidinediones will fit

Diabetes/Metabolism Research and Reviews, 2002
Individuals with type 2 diabetes have two defects: insulin resistance, which occurs in the first stages of disease progression, and pancreatic beta-cell failure, which occurs later in the disease. Insulin resistance is the major pathological defect. During the course of the disease, insulin levels are initially elevated to compensate for the increased ...
openaire   +2 more sources

Pharmacokinetic Interactions with Thiazolidinediones

Clinical Pharmacokinetics, 2007
Type 2 diabetes mellitus is a complex disease combining defects in insulin secretion and insulin action. New compounds called thiazolidinediones or glitazones have been developed for reducing insulin resistance. After the withdrawal of troglitazone because of liver toxicity, two compounds are currently used in clinical practice, rosiglitazone and ...
openaire   +2 more sources

The mode of action of thiazolidinediones

Diabetes/Metabolism Research and Reviews, 2002
The thiazolidinediones (TZDs) or 'glitazones' are a new class of oral antidiabetic drugs that improve metabolic control in patients with type 2 diabetes through the improvement of insulin sensitivity. TZDs exert their antidiabetic effects through a mechanism that involves activation of the gamma isoform of the peroxisome proliferator-activated receptor
openaire   +2 more sources

Information on thiazolidinediones

The Lancet, 2000
S M, Wolfe, P, Lurie, L D, Sasich, E, Barbehenn   +3 more
openaire   +2 more sources

Pharmacogenetics of Thiazolidinedione Therapy

Pharmacogenomics, 2007
The thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor-gamma agonists and have glucose-lowering, insulin-sensitizing and anti-inflammatory effects. TZDs are approved for the treatment of Type 2 diabetes, and have been studied as a diabetes-prevention strategy.
openaire   +2 more sources

Hepatotoxicity of thiazolidinediones

Diabetes, Obesity and Metabolism, 2001
W L, Isley, J C, Oki
openaire   +2 more sources

Thiazolidinediones

Nihon rinsho. Japanese journal of clinical medicine, 2011
Tsukasa, Nakamura, Yoshihiko, Ueda
openaire   +3 more sources